Schizophrenia is a heterogeneous psychiatric disorder that is poorly treated with current
therapies. In this brief review, we provide an update regarding the use of animal models to …

The search for immune biomarkers in psychiatric disorders has primarily focused on pro-
inflammatory cytokines. Other immune proteins including chemokines have been relatively …

Major psychiatric disorders such as schizophrenia (SZ) and bipolar disorder (BP) with
psychosis (BP+) express a complex symptomatology characterized by positive symptoms …

Schizophrenia is considered primarily as a cognitive disorder. However, functional
outcomes in schizophrenia are limited by the lack of effective pharmacological and …

Negative symptoms (eg, asociality and anhedonia) are a distinct symptomatic domain that
has been found to significantly affect the quality of life in patients diagnosed with …

Maternal exposure to infectious agents during gestation has been identified as a significant
risk factor for schizophrenia. Using a mouse model, past work has demonstrated that the …

The development of current neuroleptics was largely aiming to decrease excessive
dopaminergic signaling in the striatum. However, the notion that abnormal dopamine …

The habenula is an epithalamic structure located at the center of the dorsal diencephalic
conduction system, a pathway involved in linking forebrain to midbrain regions. Composed …

Dysregulated inflammatory responses and blood–brain barrier (BBB) dysfunction are
recognized as central factors in the development of psychiatric disorders. The present study …

Schizophrenia, a severe and debilitating disorder with a high social burden, affects 1% of
the adult world population. Available therapies are unable to treat all the symptoms, and …